The global mesalamine market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of inflammatory bowel disease (IBD) and ulcerative colitis, growing awareness about the benefits of mesalamine therapy, and increasing number of new product launches in the market. The global mesalamine market is segmented on the basis of type into capsule and tablets; on the basis of application into adult and children; and on the basis of region into North America, Latin America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA). The North American region dominates this market with a share exceeding 40%. This can be attributed to high prevalence rates for IBD in this region. 5a) Mesalamine can be used as a first-line treatment for ulcerative colitis and Crohn's disease, meaning that it may become more widely prescribed by physicians who specialize in gastroenterology or other related fields; this would also contribute to market growth because it would mean more prescriptions being written for mesalamine each year and thus more demand on the market overall (assuming no other factors change). 5b) There are currently no generic versions of mesalamine available on the market; if one were introduced at some point in the future then there would likely be increased competition among manufacturers which could lead them all lowering prices so that they're closer together (and thus making them less expensive), which could also contribute positively towards market growth over time if nothing else changes about the product or its availability on the marketplace.
Some Of The Growth Factors Of This Market:
- The global population is increasing, which will lead to an increase in the number of people with inflammatory bowel disease.
- The prevalence of inflammatory bowel disease is higher in developed countries than developing countries, and this trend is expected to continue into the future.
- Mesalamine has been shown to be effective for treating ulcerative colitis and Crohn's disease, which are both types of inflammatory bowel diseases that are expected to increase in prevalence as well.
- Mesalamine can be used as a maintenance therapy for patients who have had a response to treatment with mesalamine but have not yet achieved remission from their condition; this will also contribute to market growth because it means that patients will need mesalamine on an ongoing basis rather than just during flare-ups or periods when they experience symptoms from their condition.
Industry Growth Insights published a new data on “Mesalamine Market”. The research report is titled “Mesalamine Market research by Types (Capsule, Tablets), By Applications (Adult, Children), By Players/Companies Allergan, Salix Pharmaceuticals, Nogra Pharma, AstraZeneca, Abbvie, Takeda, Janssen (Johnson & Johnson), Pfizer, Ferring, Boehringer Ingelheim, Cosmo Pharmaceuticals, Teva, Mylan, Sandoz Mesalamine, Tillotts Pharma, Chiesi Farmaceutici, Dr Falk Pharma, Cipla, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical, Shanghai Sine Promod Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Mesalamine Market Research Report
By Type
Capsule, Tablets
By Application
Adult, Children
By Companies
Allergan, Salix Pharmaceuticals, Nogra Pharma, AstraZeneca, Abbvie, Takeda, Janssen (Johnson & Johnson), Pfizer, Ferring, Boehringer Ingelheim, Cosmo Pharmaceuticals, Teva, Mylan, Sandoz Mesalamine, Tillotts Pharma, Chiesi Farmaceutici, Dr Falk Pharma, Cipla, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical, Shanghai Sine Promod Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Mesalamine Market Report Segments:
The global Mesalamine market is segmented on the basis of:
Types
Capsule, Tablets
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Salix Pharmaceuticals
- Nogra Pharma
- AstraZeneca
- Abbvie
- Takeda
- Janssen (Johnson & Johnson)
- Pfizer
- Ferring
- Boehringer Ingelheim
- Cosmo Pharmaceuticals
- Teva
- Mylan
- Sandoz Mesalamine
- Tillotts Pharma
- Chiesi Farmaceutici
- Dr Falk Pharma
- Cipla
- Synmosa Biopharma Corporation
- Lunan Better Pharmaceutical
- Shanghai Sine Promod Pharmaceutical
Highlights of The Mesalamine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Tablets
- By Application:
- Adult
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mesalamine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mesalamine is a medication used to treat inflammation and pain. It is also used to prevent organ rejection in people who have had a kidney transplant.
Some of the major players in the mesalamine market are Allergan, Salix Pharmaceuticals, Nogra Pharma, AstraZeneca, Abbvie, Takeda, Janssen (Johnson & Johnson), Pfizer, Ferring, Boehringer Ingelheim, Cosmo Pharmaceuticals, Teva, Mylan, Sandoz Mesalamine, Tillotts Pharma, Chiesi Farmaceutici, Dr Falk Pharma, Cipla, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical, Shanghai Sine Promod Pharmaceutical.
The mesalamine market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Mesalamine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Mesalamine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Mesalamine Market - Supply Chain
4.5. Global Mesalamine Market Forecast
4.5.1. Mesalamine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Mesalamine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Mesalamine Market Absolute $ Opportunity
5. Global Mesalamine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Mesalamine Market Size and Volume Forecast by Type
5.3.1. Capsule
5.3.2. Tablets
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Mesalamine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Mesalamine Market Size and Volume Forecast by Application
6.3.1. Adult
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Mesalamine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Mesalamine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Mesalamine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Mesalamine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Mesalamine Demand Share Forecast, 2019-2026
9. North America Mesalamine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Mesalamine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Mesalamine Market Size and Volume Forecast by Application
9.4.1. Adult
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Mesalamine Market Size and Volume Forecast by Type
9.7.1. Capsule
9.7.2. Tablets
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Mesalamine Demand Share Forecast, 2019-2026
10. Latin America Mesalamine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Mesalamine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Mesalamine Market Size and Volume Forecast by Application
10.4.1. Adult
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Mesalamine Market Size and Volume Forecast by Type
10.7.1. Capsule
10.7.2. Tablets
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Mesalamine Demand Share Forecast, 2019-2026
11. Europe Mesalamine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Mesalamine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Mesalamine Market Size and Volume Forecast by Application
11.4.1. Adult
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Mesalamine Market Size and Volume Forecast by Type
11.7.1. Capsule
11.7.2. Tablets
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Mesalamine Demand Share, 2019-2026
12. Asia Pacific Mesalamine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Mesalamine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Mesalamine Market Size and Volume Forecast by Application
12.4.1. Adult
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Mesalamine Market Size and Volume Forecast by Type
12.7.1. Capsule
12.7.2. Tablets
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Mesalamine Demand Share, 2019-2026
13. Middle East & Africa Mesalamine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Mesalamine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Mesalamine Market Size and Volume Forecast by Application
13.4.1. Adult
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Mesalamine Market Size and Volume Forecast by Type
13.7.1. Capsule
13.7.2. Tablets
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Mesalamine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Mesalamine Market: Market Share Analysis
14.2. Mesalamine Distributors and Customers
14.3. Mesalamine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Salix Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Nogra Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abbvie
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Takeda
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Janssen (Johnson & Johnson)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Ferring
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Boehringer Ingelheim
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cosmo Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Teva
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Mylan
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Sandoz Mesalamine
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Tillotts Pharma
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Chiesi Farmaceutici
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Dr Falk Pharma
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Cipla
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Synmosa Biopharma Corporation
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Lunan Better Pharmaceutical
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook